Roche (SIX: RO, ROP; OTCQX: RHHBY) announces that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powered technology for pathology laboratories and the biopharma industry. This acquisition builds on the successful partnership between Roche and PathAI, established in 2021 and scaled up in 2024 to include the development of AI-enabled companion diagnostic algorithms. Under the terms of the agreement, Roche will pay a purchase price of USD 750 million upfront and additional milestone payments of up to USD 300 million.
Read the full article: Roche Enters into a Definitive Merger Agreement to Acquire PathAI to Transform AI-Driven Diagnostics //
Source: https://www.globenewswire.com/news-release/2026/05/07/3289569/0/en/roche-enters-into-a-definitive-merger-agreement-to-acquire-pathai-to-transform-ai-driven-diagnostics.html